Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours

MLA

A. Bononi, et al. “Equilibrative Nucleoside Transporter 1 Genotype, Cytidine Deaminase Activity and Age Predict Gemcitabine Plasma Clearance in Patients with Solid Tumours.” British Journal of Clinical Pharmacology, vol. 71, Feb. 2011, pp. 437–44. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........392c9c1ac8aeab3bfb1e05a9400f7782&authtype=sso&custid=ns315887.

APA

A. Bononi, Milena Gusella, Carmen Barile, C Bolzonella, Laura Stievano, Giorgio Crepaldi, Daniela Menon, Silvia Toso, Roberto Padrini, Yasmina Modena, Silvia Meneghetti, & Felice Pasini. (2011). Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. British Journal of Clinical Pharmacology, 71, 437–444.

Chicago

A. Bononi, Milena Gusella, Carmen Barile, C Bolzonella, Laura Stievano, Giorgio Crepaldi, Daniela Menon, et al. 2011. “Equilibrative Nucleoside Transporter 1 Genotype, Cytidine Deaminase Activity and Age Predict Gemcitabine Plasma Clearance in Patients with Solid Tumours.” British Journal of Clinical Pharmacology 71 (February): 437–44. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........392c9c1ac8aeab3bfb1e05a9400f7782&authtype=sso&custid=ns315887.